Increased estrogen sulfatase (STS) and 17βhydroxysteroid dehydrogenase type l(17β-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients

Breast Cancer Research and Treatment

Volumn 120, Issue 3, 2010, Pages 639-648

  Chanplakorn, Niramol ^a,b   Chanplakorn, Pongsthorn ^a,b   Suzuki, Takashi ^a   Ono, Katsuhiko ^a   Chan, Monica S M ^c   Miki, Yasuhiro ^a   Saji, Shigetoyo ^d   Ueno, Takayuki ^e   Toi, Masakazu ^e   Sasano, Hironobu ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MAHIDOL UNIVERSITY   (Thailand)

^c UNIMED Medical Institute   (Hong Kong)

^d Japanese Foundation for Multidisciplinary Treatment of Cancer   (Japan)

^e KYOTO UNIVERSITY   (Japan)

Author keywords

17 hydroxysteroid dehydrogenase; Aromatase inhibitors; Breast cancer; Estrogen sulfatase; Exemestane; Ki67

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ESTROGEN SULFATASE; ESTROGEN SULFOTRANSFERASE; EXEMESTANE; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; SULFATASE; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER STAGING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME SYNTHESIS; ESTROGEN METABOLISM; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT RESPONSE;

AGED; ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CLINICAL TRIALS, PHASE II AS TOPIC; COMBINED MODALITY THERAPY; ESTRADIOL DEHYDROGENASES; ESTROGENS; FEMALE; HUMANS; KI-67 ANTIGEN; MASTECTOMY; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; RECEPTORS, STEROID; SULFATASES; TUMOR MARKERS, BIOLOGICAL;

EID: 77950867220     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0785-3     Document Type: Article

References (41)

1. Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ (2007) Global Cancer Facts & Figures 2007. American Cancer Society, Atlanta, GA. http://www.cancer.org/docroot/STT/STT-asp. Accessed 19 Nov 2009
2. American Cancer Society (2009) Breast Cancer Facts & Figures 2009-2010. Atlanta, GA: American Cancer Society. http://www. cancer.org/docroot/STT/STT-0.asp. Accessed 19 Nov 2009
3. Pasqualini JR, Chetrite GS (2005) Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol 93:221-236
4. Chen S, Masri S, Hong YY, Wang X, Phung S, Yuan YC, Wu X (2007) New experimental models for aromatase inhibitor resistance. J Steroid Biochem Mol Biol 106:8-15. doi: 10.1016/j. jsbmb.2007.05.020 (Pubitemid 47362647)
5. Sasano H, Nagasaki S, Miki Y, Suzuki T (2009) New developments in intracrinology of human breast cancer estrogen sulfatase and sulfotransferase. Ann NY Acad Sci 1155:76-79
6. Miller WR, Forrest AP (1974) Oestradiol synthesis by a human breast carcinoma. Lancet 2:866-868
7. James VH, Reed MJ, Lai LC, Ghilchik MW, Tait GH, Newton CJ, Coldham NG (1990) Regulation of estrogen concentrations in human breast tissues. Ann NY Acad Sci 595:227-235 (Pubitemid 20282953)
8. Larionov AA, Berstein LM, Miller WR (2002) Local uptake and synthesis of oestrone in normal and malignant postmenopausal breast tissues. J Steroid Biochem Mol Biol 81:57-64
9. Miller WR, Hawkins RA, Forrest APM (1982) Significance of aromatase activity in human breast cancer. Cancer Res 42: S3365-S3368
10. Miki Y, Suzuki T, Tazawa C, Yamaguchi Y, Kitada K, Honma S, Moriya T, Hirakawa H, Evans DB, Hayashi S, Ohuchi N, Sasano H (2007) Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells. Cancer Res 67:3945-3954 (Pubitemid 46762184)
11. Sasano H, Harada N (1998) Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. Endocr Rev 19:593-607 (Pubitemid 28467713)
12. Santen RJ, Leszczynski D, Tilson-Mallet N, Feil PD, Wright C, Manni A, Santner S (1986) Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways. Ann N Y Acad Sei 464:126-137 (Pubitemid 17197627)
13. Miller WR, Anderson TJ, Jack WJL (1990) Relationship between tumour aromatase activity, tumour characteristics and response to therapy. J Steroid Biochem Mol Biol 37:1055-1059
14. 14. Suzuki T, Nakata T, Miki Y, Kaneko C, Moriya T, Ishida T, Akinaga S, Hirakawa H, Kimura M, Sasano H (2003) Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Res 63:2762-2770 (Pubitemid 36667146)
15. Sasano H, Suzuki T, Nakata T, Moriya T (2006) New development in intracrinology of breast carcinoma. Breast Cancer 13: 129-136
16. Santen RJ (2003) Inhibition of aromatase: insights from recent studies. Steroids 68:559-567
17. Miller WR, Anderson TJ, White S, Larionov A, Murray J, Evans D, Krause A, Dixon JM (2005) Aromatase inhibitors: cellular and molecular effects. J Steroid Biochem Mol Biol 95:83-89 (Pubitemid 41137297)
18. Geisler J (2008) Aromatase inhibitors: from bench to bedside and back. Breast Cancer 15:17-26
19. Geisler J, Lønning PE (2005) Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res 11:28092821 (Pubitemid 40525179)
20. Masri S, Phung S, Wang X, Wu X, Yuan YC, Wagman L, Chen S (2008) Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor. Cancer Res 68:4910-4918
21. Lønning PE (2009) Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? Eur J Cancer 45:527-535
22. Santen RJ, Lobenhofer EK, Afshari CA, Bao Y, Song RX (2005) Adaptation of estrogen-regulated genes in long-term estradiol deprived MCF-7 breast cancer cells. Breast Cancer Res Treat 94:213-223 (Pubitemid 41677626)
23. Brodie A, Macedo L, Sabnis G (2009) Aromatase resistance mechanisms in model system in vivo. J Steroid Biochem Mol Biol. doi:10.1016/j.jsbmb.2009.09. 004
24. Flågeng MH, Moi LL H, Dixon JM, Geisler J, Lien EA, Miller WR, Lønning PE, Mellgren G (2009) Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. Br J Cancer 101:1253-1260
25. Sato N, Masuda N, Saji S, Takei H, Yamamoto Y, Sasano H, Toi M (2009) Neoadjuvant exemestane for 24 weeks in postmenopausal women with hormone receptor positive stage II or IUa breast cancer (JFMC34-0601) [abstract 591]. J Clin Oncol 27:15S
26. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Glabbeke MV, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216 (Pubitemid 30099779)
27. Miller WR, White S, Dixon JM, Murray J, Renshaw L, Anderson TJ (2006) Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. Br J Cancer 94:1051-1056
28. Bouzubar N, Walker KJ, Griffiths K, Ellis IO, Elston CW, Robertson JFR, Blarney RW, Nicholson RI (1989) Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 59:943-947 (Pubitemid 19155714)
29. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481
30. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145 (Pubitemid 350003059)
31. Takei H, Suemasu K, Inoue K, Saito T, Okubo K, Koh J, Sato K, Tsuda H, Kurosumi M, Tabei T (2008) Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03). Breast Cancer Res Treat 107:87-94
32. Mlineritsch B, Tausch C, Singer C, Luschin-Ebengreuth G, Jakesz R, Ploner F, Stierer M, Melbinger E, Menzel C, Urbania A, Fridrik M, Steger G, Wohlmuth P, Gnant M, Greil R (2008) Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17). Breast Cancer Res Treat 112:203-213
33. Yamashita H, Takahashi S, Ito Y, Yamashita T, Ando Y, Toyama T, Sugiura H, Yoshimoto N, Kobayashi S, Fujii Y, Iwase H (2009) Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. Cancer Sci. 100:2028-2033
34. Barnadas A, Gil M, Gonzalez S, Tusquets I, Munoz M, Arcusa A, Prieto L, Margeli-Vila M, Moreno A (2009) Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial. Br J Cancer 100: 442-449
35. Miller WR, Dixon JM, Macfarlane L, Cameron D, Anderson TJ (2003) Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur J Cancer 39:462-468 (Pubitemid 36173690)
36. Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, Smith IE (2005) Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer-a study from the IMPACT trialists. J Clin Oncol 23:2477-2492 (Pubitemid 47050838)
37. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, Salter J, Detre S, Hills M, Walsh G (2007) Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99:167-170
38. Anderson H, Bulun S, Ian Smith, Dowsett M (2007) Predictors of response to aromatase inhibitors. J Steroid Biochem Mol Biol 106:49-54
39. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, Miller WR, Evans DB, Dugan M, Brady C, QuebeFehling E, Borgs M. (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J CIi Oncol 19:3808-3816
40. Suzuki T, Moriya T, Ariga N, Kaneko C, Kanazawa M, Sasano H (2000) 1 Jbeta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. Br J Cancer 82:518-523 (Pubitemid 30085183)
41. Aka JA, Mazumdar M, Lin SX (2009) Reductive 17β-hydroxysteroid dehydrogenases in the sulfatase pathway: Critical in the cell proliferation of breast cancer. Mol Cell Endocrinol 301: 183-190